biostudies-literatureMahil SKPsoriasis AssociationMedical Research CouncilNational Institute for Health Research (NIHR)NIHR Manchester Biomedical Research CentreDepartment of Health via the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London80-90https://www.ebi.ac.uk/biostudies/studies/S-EPMC9214088biostudies-literatureUnknown185(1)<h4>Background</h4>Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments.<h4>Objectives</h4>We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation.<h4>Methods</h4>Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical The British journal of dermatologyRisk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.PMC9214088PsoProtectNF-SI-0512-10105NF-SI-0617-10075MR/T02383X/1MR/S003126/1Langan SMYates MTorres TPuig LSmith CHYiu ZZNLambert JCoker BMoorhead LDand NCapon FVesty ADe La Cruz CKelly JContreras CRMarzo-Ortega HHyrich KMcAteer HSengupta RBruce INMason KJBrown MANaldi LSpuls PBarker JNMahil SKMcInnes ICope APMeynell FGisondi PDi Meglio PUrmston DGriffiths CEMGalloway JBTsakok TWeinman JWarren RBPsoProtect, CORE-UK study groupsNorton SWaweru HVincent ALancelot CBachelez HJullien DfalseRisk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey.<h4>Background</h4>Registry data suggest that people with immune-mediated inflammatory diseases (IMIDs) receiving targeted systemic therapies have fewer adverse coronavirus disease 2019 (COVID-19) outcomes compared with patients receiving no systemic treatments.<h4>Objectives</h4>We used international patient survey data to explore the hypothesis that greater risk-mitigating behaviour in those receiving targeted therapies may account, at least in part, for this observation.<h4>Methods</h4>Online surveys were completed by individuals with psoriasis (globally) or rheumatic and musculoskeletal diseases (RMDs) (UK only) between 4 May and 7 September 2020. We used multiple logistic regression to assess the association between treatment type and risk-mitigating behaviour, adjusting for clinical 2021-01-01T00:00:00Z2021 Jul2025-04-04T03:06:26.122Z2025-02-19T05:06:21.835ZS-EPMC92140883336814510.1111/bjd.19755